Systemic Therapy for Melanoma

Neoadjuvant pembrolizumab (maximum of 3 courses of 200 mg once every 3 weeks) followed by resection and adjuvant pembrolizumab (maximum of 15 courses of 200 mg once every 3 weeks) should be offered to patients with clinical and resectable stage IIIB–IV cutaneous melanoma. ( EB , M, B , S )

Patients with clinical and resectable stage IIIB–IV cutaneous melanoma should be offered or referred for enrollment in clinical trials of neoadjuvant therapy where possible. ( IC , , , S )